Think You Have A “Breakthrough” Drug? Think Again, FDA’s Woodcock Says
Executive Summary
CDER director says breakthrough designation requests are frequently denied because evidence suggests only an incremental advance over standard therapy; other reasons for denial include showing no clinical advantage and a development program being placed on clinical hold.
You may also be interested in...
“Breakthrough” Review: FDA And Sponsors Discuss Ways To Improve Efficiency
Pharmacyclics exec says PDUFA V “program” meetings should be optional, as timelines for mid-cycle communication and late-cycle meeting are out of sync with highly compressed review times for some products. CDER is internally discussing whether it would be feasible to give breakthrough therapy sponsors a target date for approval.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.